Drugs / PRO-232
last change Jul 2026 re-read 2 minutes ago

PRO-232

Developed for
cataract
Investigated by
Laboratorios Sophia S.A de C.V.

Trials 1 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT07305987 Oct 2025 → Jun 2026 overdue cataract Laboratorios Sophia S.A de C.V. Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as PRO-232 “The main objective of this study is to evaluate the efficacy and safety of the PRO-232 formulation manufactured by Laboratorios Sophia S.A. de C.V. on the ocular surface of...” NCT07305987
Route Topical “PRO-232 ophthalmic solution applied to the ocular surface of postoperative cataract patients” NCT07305987